Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 12, 2016 (10 years ago)

Levothyroxine Sodium 135 mcg/Liothyronine 15 mcg SR capsules

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Superpotent Drug and Subpotent Drug; potency failures obtained

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Levothyroxine Sodium 135 mcg/Liothyronine 15 mcg SR capsules, 90 count bottles, Rx only, Moore's Pharmacy Compounding, Corpus Christi, TX

Drug: Levothyroxine Category: Thyroid Medication

Recalling firm
Moore's Compounding Pharmacy
Origin
TX, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0488-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levothyroxine recalls

See all

Other wrong potency / content recalls from 2016

All wrong potency / content recalls
Class III · Low risk

Aripiprazole Tablets

Superpotent Drug; out of specification results for assay (manufacturer)

Terminated Wrong potency / content The Harvard Drug Group NDC 0904-6509-04 D-0692-2017